중개 재생의료 시장(2024-2034년)

The global Translational Regenerative Medicine market is estimated to grow at a CAGR of 24.3% by 2034

The Translational Regenerative Medicine Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Rising Chronic Diseases Driving Industry Growth

The global landscape of healthcare is witnessing a paradigm shift driven by the escalating prevalence of chronic diseases. Conditions such as cardiovascular diseases, diabetes, neurodegenerative disorders, and autoimmune diseases pose a significant burden on healthcare systems worldwide. In response to this growing health crisis, the field of Translational regenerative medicine (TRM) has emerged as a beacon of hope, offering innovative solutions to address the root causes of these chronic ailments. Translational regenerative medicine focuses on harnessing the body's innate regenerative capabilities to repair, replace, or regenerate damaged tissues and organs. Stem cell therapies, tissue engineering, and other regenerative approaches hold the potential to revolutionize the treatment landscape for chronic diseases by addressing the underlying causes rather than merely managing symptoms. Translational regenerative medicine allows for the development of personalized therapies tailored to individual patient needs. This approach is particularly relevant in the context of chronic diseases where heterogeneity in patient responses is common. Advances in stem cell research, including the use of induced pluripotent stem cells (iPSCs) and adult stem cells, offer a diverse range of regenerative possibilities. Stem cell-based therapies hold promise for conditions such as diabetes, where the replacement of damaged pancreatic cells could restore normal insulin production.

High Development Costs Associated with Translational Regenerative Medicine

The initial phases of developing translational regenerative medicine therapies involve extensive research to understand the underlying biology and mechanisms. This early-stage research requires funding for laboratory equipment, personnel, and consumables. Clinical trials represent a major portion of the development costs. These trials are essential for evaluating the safety and efficacy of regenerative therapies in human subjects. Costs include patient recruitment, monitoring, regulatory compliance, and data analysis, all of which demand substantial financial resources. Transitioning from laboratory-scale production to large-scale manufacturing presents unique challenges. Ensuring the reproducibility, quality, and safety of regenerative therapies on a larger scale requires investment in manufacturing infrastructure and process optimization. Successfully bringing a regenerative medicine product to market is just the beginning. Companies face additional costs related to market access, including marketing, distribution, and post-marketing surveillance. These activities are crucial for ensuring widespread adoption and continued success.

What Questions Should You Ask before Buying a Market Research Report?

How is the Translational Regenerative Medicine Market evolving?

What is driving and restraining the Translational Regenerative Medicine Market?

How will each Translational Regenerative Medicine submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each Translational Regenerative Medicine submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading Translational Regenerative Medicine Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the Translational Regenerative Medicine projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of Translational

Regenerative Medicine projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the Translational Regenerative Medicine Market?

Where is the Translational Regenerative Medicine Market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Translational Regenerative Medicine Market today, and over the next 10 years:

Our 270-page report provides 104 tables and 144 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Translational Regenerative Medicine Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

By Product

Stem Cell Therapy: Autologous, Allogenic

Tissue Engineering: Scaffold, Hydrogels

Gene Therapy

Others

By Application

Oncology

Dermatology

Musculoskeletal

Neurology

Cardiovascular

Wound Healing

Ophthalmology

Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 17 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Translational Regenerative Medicine Market 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

Amgen Inc.

Anterogen Co., Ltd.

AVITA Medical, Inc.

Biosolutions Ltd.

bluebird bio, Inc.

Bristol-Myers Squibb Company

Gilead Sciences, Inc.

Integra LifeSciences

Mesoblast Ltd.

Novartis AG

Organogenesis Inc.

Sarepta Therapeutics, Inc.

Smith+Nephew

TERUMO BCT, INC.

Overall world revenue for Translational Regenerative Medicine Market, 2024 to 2034 in terms of value the market will surpass US$77.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Translational Regenerative Medicine Market 2024 to 2034 report help you?

In summary, our 270-page report provides you with the following knowledge:

Revenue forecasts to 2034 for Translational Regenerative Medicine Market 2024 to 2034, with forecasts for product and application each forecasted at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 20 key national markets - See forecasts for the Translational Regenerative Medicine Market, 2024 to 2034 in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 14 of the major companies involved in the Translational Regenerative Medicine Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Translational Regenerative Medicine Market 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Translational Regenerative Medicine Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report
• 1.6 Who is This Report for?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
  • 3.2.1 Market Driving Factors
    • 3.2.1.1 Increasing Strategic Activities and Collaborations
    • 3.2.1.2 Rise in Research and Development Projects
    • 3.2.1.3 Surging Government Support
    • 3.2.1.4 Growing Focus on Personalized Medicine
    • 3.2.1.5 Emerging Applications in New Therapeutic Areas
    • 3.2.1.6 Increasing Collaborations and Partnerships by Major Market Players
    • 3.2.1.7 Increasing Regulatory Approvals in Regenerative Medicine
  • 3.2.2 Market Restraining Factors
    • 3.2.2.1 Substantial Number of Product Recalls
    • 3.2.2.2 Unapproved Products in the Market
    • 3.2.2.3 Reimbursement Policies
    • 3.2.2.4 High Cost of Treatments
  • 3.2.3 Market Opportunities
    • 3.2.3.1 Growing Research Partnership in Developed and Developing Countries Across the Globe
    • 3.2.3.2 Growing Awareness About the Advances in Medical Research
    • 3.2.3.3 Growing Investment and Funding
    • 3.2.3.4 Harnessing the Potential of 3D Printing
    • 3.2.3.5 Integration with Artificial Intelligence and Big Data
    • 3.2.3.6 Growing Number of Organ Transplants
• 3.3 COVID-19 Impact Analysis
• 3.4 Porter's Five Forces Analysis
  • 3.4.1 Bargaining Power of Suppliers
  • 3.4.2 Bargaining Power of Buyers
  • 3.4.3 Competitive Rivalry
  • 3.4.4 Threat from Substitutes
  • 3.4.5 Threat of New Entrants
• 3.5 PEST Analysis

4 Translational Regenerative Medicine Market Analysis by Product

• 4.1 Key Findings
• 4.2 Application Segment: Market Attractiveness Index
• 4.3 Translational Regenerative Medicine Market Size Estimation and Forecast by Product
• 4.4 Stem Cell Therapy
  • 4.4.1 Translational Regenerative Medicine Market Size Estimation and Forecast by Stem Cell Therapy
  • 4.4.2 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.4.3 Market Share by Region, 2024 & 2034 (%)
  • 4.4.4 Autologous Stem Cell Therapy
    • 4.4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.4.5 Allogenic
    • 4.4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.4.5.2 Market Share by Region, 2024 & 2034 (%)
• 4.5 Tissue Engineering
  • 4.5.1 Translational Regenerative Medicine Market Size Estimation and Forecast by Tissue Engineering
  • 4.5.2 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.5.3 Market Share by Region, 2024 & 2034 (%)
  • 4.5.4 Scaffold
    • 4.5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.5.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5.5 Hydrogels
    • 4.5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.5.5.2 Market Share by Region, 2024 & 2034 (%)
• 4.6 Gene Therapy
  • 4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.6.2 Market Share by Region, 2024 & 2034 (%)
• 4.7 Others
  • 4.7.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.7.2 Market Share by Region, 2024 & 2034 (%)

5 Translational Regenerative Medicine Market Analysis by Application

• 5.1 Key Findings
• 5.2 Application Segment: Market Attractiveness Index
• 5.3 Translational Regenerative Medicine Market Size Estimation and Forecast by Application
• 5.4 Oncology
  • 5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.4.2 Market Share by Region, 2024 & 2034 (%)
• 5.5 Dermatology
  • 5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.5.2 Market Share by Region, 2024 & 2034 (%)
• 5.6 Musculoskeletal
  • 5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.6.2 Market Share by Region, 2024 & 2034 (%)
• 5.7 Neurology
  • 5.7.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.7.2 Market Share by Region, 2024 & 2034 (%)
• 5.8 Cardiovascular
  • 5.8.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.8.2 Market Share by Region, 2024 & 2034 (%)
• 5.9 Wound Healing
  • 5.9.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.9.2 Market Share by Region, 2024 & 2034 (%)
• 5.10 Ophthalmology
  • 5.10.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.10.2 Market Share by Region, 2024 & 2034 (%)
• 5.11 Others
  • 5.11.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.11.2 Market Share by Region, 2024 & 2034 (%)

6 Translational Regenerative Medicine Market Analysis by Region

• 6.1 Key Findings
• 6.2 Regional Market Size Estimation and Forecast

7 North America Translational Regenerative Medicine Market Analysis

• 7.1 Key Findings
• 7.2 North America Translational Regenerative Medicine Market Attractiveness Index
• 7.3 North America Translational Regenerative Medicine Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 7.4 North America Translational Regenerative Medicine Market Size Estimation and Forecast by Country
• 7.5 North America Translational Regenerative Medicine Market Size Estimation and Forecast by Product
• 7.6 North America Translational Regenerative Medicine Market Size Estimation and Forecast by Application
• 7.7 U.S. Translational Regenerative Medicine Market Analysis
• 7.8 Canada Translational Regenerative Medicine Market Analysis

8 Europe Translational Regenerative Medicine Market Analysis

• 8.1 Key Findings
• 8.2 Europe Translational Regenerative Medicine Market Attractiveness Index
• 8.3 Europe Translational Regenerative Medicine Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 8.4 Europe Translational Regenerative Medicine Market Size Estimation and Forecast by Country
• 8.5 Europe Translational Regenerative Medicine Market Size Estimation and Forecast by Product
• 8.6 Europe Translational Regenerative Medicine Market Size Estimation and Forecast by Application
• 8.7 Germany Translational Regenerative Medicine Market Analysis
• 8.8 France Translational Regenerative Medicine Market Analysis
• 8.9 UK Translational Regenerative Medicine Market Analysis
• 8.10 Italy Translational Regenerative Medicine Market Analysis
• 8.11 Spain Translational Regenerative Medicine Market Analysis
• 8.12 Russia Translational Regenerative Medicine Market Analysis
• 8.13 Rest of Europe Translational Regenerative Medicine Market Analysis

9 Asia Pacific Translational Regenerative Medicine Market Analysis

• 9.1 Key Findings
• 9.2 Asia Pacific Translational Regenerative Medicine Market Attractiveness Index
• 9.3 Asia Pacific Translational Regenerative Medicine Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 9.4 Asia Pacific Translational Regenerative Medicine Market Size Estimation and Forecast by Country
• 9.5 Asia Pacific Translational Regenerative Medicine Market Size Estimation and Forecast by Product
• 9.6 Asia Pacific Translational Regenerative Medicine Market Size Estimation and Forecast by Application
• 9.7 Japan Translational Regenerative Medicine Market Analysis
• 9.8 China Translational Regenerative Medicine Market Analysis
• 9.9 India Translational Regenerative Medicine Market Analysis
• 9.10 Australia Translational Regenerative Medicine Market Analysis
• 9.11 South Korea Translational Regenerative Medicine Market Analysis
• 9.12 Rest of Asia Pacific Translational Regenerative Medicine Market Analysis

10 Latin America Translational Regenerative Medicine Market Analysis

• 10.1 Key Findings
• 10.2 Latin America Translational Regenerative Medicine Market Attractiveness Index
• 10.3 Latin America Translational Regenerative Medicine Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 10.4 Latin America Translational Regenerative Medicine Market Size Estimation and Forecast by Country
• 10.5 Latin America Translational Regenerative Medicine Market Size Estimation and Forecast by Product
• 10.6 Latin America Translational Regenerative Medicine Market Size Estimation and Forecast by Application
• 10.7 Brazil Translational Regenerative Medicine Market Analysis
• 10.8 Mexico Translational Regenerative Medicine Market Analysis
• 10.9 Rest of Latin America Translational Regenerative Medicine Market Analysis

11 MEA Translational Regenerative Medicine Market Analysis

• 11.1 Key Findings
• 11.2 MEA Translational Regenerative Medicine Market Attractiveness Index
• 11.3 MEA Translational Regenerative Medicine Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 11.4 MEA Translational Regenerative Medicine Market Size Estimation and Forecast by Country
• 11.5 MEA Translational Regenerative Medicine Market Size Estimation and Forecast by Product
• 11.6 MEA Translational Regenerative Medicine Market Size Estimation and Forecast by Application
• 11.7 GCC Translational Regenerative Medicine Market Analysis
• 11.8 South Africa Translational Regenerative Medicine Market Analysis
• 11.9 Rest of MEA Translational Regenerative Medicine Market Analysis

12 Company Profiles

• 12.1 Competitive Landscape, 2022
• 12.2 Strategic Outlook
• 12.3 Amgen Inc.
  • 12.3.1 Company Snapshot
  • 12.3.2 Company Overview
  • 12.3.3 Financial Analysis
    • 12.3.3.1 Net Revenue, 2017-2022
    • 12.3.3.2 R&D, 2017-2022
    • 12.3.3.3 Regional Market Shares, 2022
  • 12.3.4 Product Benchmarking
  • 12.3.5 Strategic Outlook
• 12.4 Anterogen Co., Ltd.
  • 12.4.1 Company Snapshot
  • 12.4.2 Company Overview
  • 12.4.3 Product Benchmarking
• 12.5 AVITA Medical, Inc.
  • 12.5.1 Company Snapshot
  • 12.5.2 Company Overview
  • 12.5.3 Financial Analysis
    • 12.5.3.1 Net Revenue, 2017-2022
    • 12.5.3.2 R&D, 2017-2022
  • 12.5.4 Product Benchmarking
  • 12.5.5 Strategic Outlook
• 12.6 Biosolutions Ltd.
  • 12.6.1 Company Snapshot
  • 12.6.2 Company Overview
  • 12.6.3 Product Benchmarking
  • 12.6.4 Strategic Outlook
• 12.7 bluebird bio, Inc.
  • 12.7.1 Company Snapshot
  • 12.7.2 Company Overview
  • 12.7.3 Financial Analysis
    • 12.7.3.1 Net Revenue, 2017-2022
    • 12.7.3.2 R&D, 2017-2022
  • 12.7.4 Product Benchmarking
  • 12.7.5 Strategic Outlook
• 12.8 Bristol-Myers Squibb Company
  • 12.8.1 Company Snapshot
  • 12.8.2 Company Overviews
  • 12.8.3 Financial Analysis
    • 12.8.3.1 Net Revenue, 2017-2022
    • 12.8.3.2 R&D, 2017-2022
    • 12.8.3.3 Regional Market Shares, 2022
  • 12.8.4 Product Benchmarking
  • 12.8.5 Strategic Outlook
• 12.9 Gilead Sciences, Inc.
  • 12.9.1 Company Snapshot
  • 12.9.2 Company Overview
  • 12.9.3 Financial Analysis
    • 12.9.3.1 Net Revenue, 2017-2022
    • 12.9.3.2 R&D, 2017-2022
    • 12.9.3.3 Regional Market Shares, 2022
  • 12.9.4 Product Benchmarking
  • 12.9.5 Strategic Outlook
• 12.10 Integra LifeSciences
  • 12.10.1 Company Snapshot
  • 12.10.2 Company Overview
  • 12.10.3 Financial Analysis
    • 12.10.3.1 Net Revenue, 2017-2022
    • 12.10.3.2 R&D, 2017-2022
    • 12.10.3.3 Regional Market Shares, 2022
  • 12.10.4 Product Benchmarking
  • 12.10.5 Strategic Outlook
• 12.11 Mesoblast Ltd.
  • 12.11.1 Company Snapshot
  • 12.11.2 Company Overview
  • 12.11.3 Financial Analysis
    • 12.11.3.1 Net Revenue, 2017-2022
    • 12.11.3.2 R&D, 2017-2022
  • 12.11.4 Product Benchmarking
  • 12.11.5 Strategic Outlook
• 12.12 Novartis AG
  • 12.12.1 Company Snapshot
  • 12.12.2 Company Overview
  • 12.12.3 Financial Analysis
    • 12.12.3.1 Net Revenue, 2017-2022
    • 12.12.3.2 R&D, 2017-2022
    • 12.12.3.3 Regional Market Shares, 2022
  • 12.12.4 Product Benchmarking
  • 12.12.5 Strategic Outlook
• 12.13 Organogenesis Inc.
  • 12.13.1 Company Snapshot
  • 12.13.2 Company Overview
  • 12.13.3 Financial Analysis
    • 12.13.3.1 Net Revenue, 2017-2022
    • 12.13.3.2 R&D, 2017-2022
  • 12.13.4 Product Benchmarking
  • 12.13.5 Strategic Outlook
• 12.14 Sarepta Therapeutics, Inc.
  • 12.14.1 Company Snapshot
  • 12.14.2 Company Overview
  • 12.14.3 Financial Analysis
    • 12.14.3.1 Net Revenue, 2017-2022
    • 12.14.3.2 R&D, 2017-2022
  • 12.14.4 Product Benchmarking
  • 12.14.5 Strategic Outlook
• 12.15 Smith+Nephew
  • 12.15.1 Company Snapshot
  • 12.15.2 Company Overview
  • 12.15.3 Financial Analysis
    • 12.15.3.1 Net Revenue, 2017-2022
    • 12.15.3.2 R&D, 2017-2022
    • 12.15.3.3 Regional Market Shares, 2022
  • 12.15.4 Product Benchmarking
  • 12.15.5 Strategic Outlook
• 12.16 TERUMO BCT, INC.
  • 12.16.1 Company Snapshot
  • 12.16.2 Company Overview
  • 12.16.3 Financial Analysis
    • 12.16.3.1 Net Revenue, 2017-2022
    • 12.16.3.2 Regional Market Shares, 2021
  • 12.16.4 Product Benchmarking
  • 12.16.5 Strategic Outlook

13 Conclusion and Recommendations

• 13.1 Concluding Remarks from Visiongain
• 13.2 Recommendations for Market Players